Jeffrey Murray, MD, MPH, Program Advisor
Jeffrey S. Murray, MD, MPH is a Program Advisor at the Forum for Collaborative Research and the 1st recipient of the John G. Bartlett Award for "Catalyzing Clinical Research to Improve Global Health" sponsored by the Forum for Collaborative Research. He served as Deputy Director of the Division of Antiviral Products at the US Food and Drug Administration. Being with the agency for over twenty-nine years, he made significant contributions on three major areas of innovation that revolutionized treatment and prevention for infectious diseases: viral load as an endpoint for antiretroviral trials; historical controls for hepatitis C direct-acting antiviral agents’ trials; and most recently - exploring the use of a counterfactual estimate of HIV incidence for use as a control in HIV prevention trials. He helped guide the Division throughout his years of service, applying the lessons learned from HIV to subsequent viral illnesses, most recently, COVID-19.
He has co-authored many publications and FDA guidance documents for HIV drug development, HIV fixed-dose combinations for the President’s Emergency Plan for AIDS Relief (PEPFAR), and the development of drugs for the treatment of Influenza and Chronic Hepatitis C.
Dr. Murray, a longtime collaborator and friend of the Forum for Collaborative Research, has been instrumental in the HIV, HCV, HBV and TAVI Forum initiatives, including meta-analysis of CMV DNAemia as a surrogate marker in transplantation patients, standardization of HCV response nomenclature, innovation in HIV clinical trial design to accommodate new drug resistance information, and monitoring for safety in long-term treatment.
He has co-authored many publications and FDA guidance documents for HIV drug development, HIV fixed-dose combinations for the President’s Emergency Plan for AIDS Relief (PEPFAR), and the development of drugs for the treatment of Influenza and Chronic Hepatitis C.
Dr. Murray, a longtime collaborator and friend of the Forum for Collaborative Research, has been instrumental in the HIV, HCV, HBV and TAVI Forum initiatives, including meta-analysis of CMV DNAemia as a surrogate marker in transplantation patients, standardization of HCV response nomenclature, innovation in HIV clinical trial design to accommodate new drug resistance information, and monitoring for safety in long-term treatment.
John Sninsky, PhD, Program Advisor
John Sninsky, PhD is a Program Advisor at the Forum and a Visiting Professor in the Division of Infectious Disease and Vaccinology at the Berkeley School of Public Health. John is also a Translational Science and Medicine consultant with a comprehensive and deep understanding of the development and application of pioneering molecular procedures to the translation of research-grade biomarker assays into clinical-grade clinically adopted diagnostic tests. Following a faculty appointment at Albert Einstein College of Medicine, John joined the team at Cetus that developed polymerase chain reaction (PCR) and applied the powerful technology to clinical virology diagnostics, notably HIV. He has held senior management positions at Roche, Celera, Quest Diagnostics and CareDx.
John is the author of more than 110 scientific papers including advanced methods in molecular biology, application of the polymerase chain reaction (PCR) to virology and cancer, and genome-wide genetic association studies for multiple common, complex diseases. John advises commercial translation efforts at Stanford University (SPARK) and University of California, San Francisco (CATALYST) and lectures in Diagnostic Regulatory Science at University of California, Berkeley. He is a member of Coronavirus Standards Working Group, an organization focused on developing molecular standards for SARS-CoV-2 (COVID-19). John also serves as a technical advisor for Stop the Spread, with a focus on diagnostics.
John is the author of more than 110 scientific papers including advanced methods in molecular biology, application of the polymerase chain reaction (PCR) to virology and cancer, and genome-wide genetic association studies for multiple common, complex diseases. John advises commercial translation efforts at Stanford University (SPARK) and University of California, San Francisco (CATALYST) and lectures in Diagnostic Regulatory Science at University of California, Berkeley. He is a member of Coronavirus Standards Working Group, an organization focused on developing molecular standards for SARS-CoV-2 (COVID-19). John also serves as a technical advisor for Stop the Spread, with a focus on diagnostics.